MST-188 – Trauma
Recently, the Company signed a Cooperative Research and Development Agreement with a branch of the U.S. military to evaluate the utility of MST-188 in specific models of trauma of interest to the U.S. government. Pilot studies are expected to begin in 2014. If results are positive, the Company expects the U.S. government will be interested in further exploring the potential of MST-188 as a treatment following major trauma.
Has that been announced previously?
Prepare for a nice jump on Thursday.
Vista is $2.25. Laidlaw just initiated at $2.50 and that's why Yahoo changed the target price.
How many announcements are expected in Q3? What quarter are we halfway through? Where do announcements happen? What's occurring in one week? All questions that have definitive answers.
His strategy has nothing to do with your timeline. If this thing is up 400% in 15 months do you think his strategy will be a success? yeah, me too.
Today Laidlaw initiated coverage of MSTX with a BUY rating and a $2.50 price target. This comes one day after Vista Partners reiterated its BUY rating on Mast with a $2.25 price target. Both analysts now expecting 400% increases in share price within a year. That's why we are seeing double volume with this nice jump today.
they are still scheduled to report results in 3rd quarter. we are halfway through the 3rd quarter which means we are merely moments away from getting news.
Reminder that MSTX will be announcing a ton of news in 3rd quarter...and they are hosting the Sickle Cell convention in mid September. You do the math.
read part of newsletter
Mast Therapeutics, Inc. (MSTX)
Current Price: $0.57
Target Price: $2.25
Mast Therapeutics, Inc. (the “Company” or “MSTX”) is a biopharmaceutical company headquartered in
San Diego, California. The Company is leveraging the MAST (Molecular Adhesion and Sealant
Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing
experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate,
for serious or life-threatening diseases with significant unmet needs. MST-188 is a cytoprotective,
hemorheologic, anti-inflammatory and anti-thrombotic (preventing blood clots) agent that has potential
utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction
and/or impaired blood flow), such as heart attack, stroke, sickle cell disease, limb ischemia, heart failure,
hemorrhagic shock and other conditions of impaired blood flow. The Company is currently enrolling
subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease.
Per MSTX CEO Brian Culley’s blog, MAST recently initiated a nonclinical study of MST-188 in an
experimental model of thrombotic stroke to evaluate MST-188’s potential to improve the therapeutic
effect of rt-PA and expand the window in which it is effective. If MST-188 increases the therapeutic
benefits of rt-PA in this nonclinical model and our phase 2 study in ALI demonstrates that MST-188 in
combination with rt-PA accelerates time-to-reperfusion, MAST believes there will be interest from
potential partners to develop MST-188 in stroke, a major market opportunity.
For the phase 2 asset MAST obtained via the acquisition of Aires Pharmaceuticals earlier this year, MAST
recently locked the database for 20 patients who completed treatment in Aires’ phase 2 study in
patients with pulmonary arterial hypertension. MAST anticipates announcing data from this trial in the
third quarter of 2014. This
what's going on is the recognition that there is a big need for treatment in this area that has been unmet. how many companies are working towards cancer treatments...thousands...this is good news. if our product works...there will be a huge market for it. perhaps this small company acquired didn't have funds to continue the study and sold cheap. perhaps mstx has plenty of cash and is bullish on their ability to go it alone to get a superior price down the line. what do you know? nothing. what we do know is there is an unmet need for treatment---more than one is fine---and if our product works---we do very well. nothing has changed.
we're hanging tough in our holding pattern. at any news release we know what will happen----and there are 4 or 5 left for the remainder of the year...less than 6 months. perhaps one every month or so---will be a good run into 2015, for sure.
they are not in the dark---you are. So what. I know that a big tell is the huge stock options plan that was just approved by the board and shareholders which covers the next 5 years. The purchase price will always be .65 and they vest slowly each and every month for the next 3-5 years, depending. Most stock options allow for periods of time to set price based on the lowest price at the start or end of a period of time. That allows for employees to buy in at lower prices should the stock fall. That isn't the plan here. And this is for an extended period of time with millions of shares, also very unusual. This says they fully expect GREAT things in the future and the option for a lower stock price is not an option, literally.
According to the new 8K just released Mast Therapeutics is moving into the office space formerly held by the 200 employee strong Santarus Pharma company---which was acquired recently by Salix Pharma. Looks like Mast is clearly preparing to be a multi billilon dollar company like Santarus was when it was purchased. That space is significant. Big development!